1. People's Republic of China Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Kingfa Sci. & Tech. Co., Ltd.

Kingfa Sci. & Tech. Co., Ltd.

600143.SS
Kingfa Sci. & Tech. Co., Ltd.CN flagShanghai Stock Exchange
15.21
CNY
+0.09
- -
39.72BMarket Cap
Kingfa Sci. & Tech. Co., Ltd.
600143.SS
(Shanghai Stock Exchange)

Recent

price

15.21

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
3.1
4.53
5.2
4.73
5.54
6.14
6.17
7.03
8.52
9.32
11.15
13.62
15.62
15.58
18.01
22.9
26.08
Revenue per Share
0.12
0.26
0.43
0.3
0.29
0.19
0.28
0.29
0.2
0.23
0.47
1.78
0.65
0.77
0.12
0.31
0.39
Basic EPS, GAAP
-0.02
0.03
-0.16
-0.14
-0.05
0.04
-0.01
-0.42
-0.37
-0.31
0.55
1.32
-1.59
-1.41
-0.72
0.17
-0.89
Free Cash Flow per Basic Share
0.11
0.14
0.15
0.23
0.25
0.15
0.14
0.17
0.2
0.2
0.29
0.31
0.81
0.53
0.68
0.43
0.57
Dividend per Share
1.02
1.21
1.56
1.72
1.78
1.82
2.01
2.22
2.19
2.3
2.68
4.35
4.33
4.76
4.52
4.75
4.89
Book Value per Share
1.26
1.38
1.79
2.76
2.71
2.65
2.64
3.11
3.09
3.19
3.08
4.76
5.18
5.61
5.28
6.44
6.36
Tangible Book Value per Share
2,292
2,260
2,219
2,589
2,603
2,623
2,542
2,560
2,717
2,717
2,626
2,574
2,574
2,595
2,662
2,643
2,638
Basic Weighted Avg Shares
7,112
10,242
11,547
12,240
14,426
16,094
15,682
17,991
23,137
25,317
29,286
35,061
40,199
40,412
47,941
60,514
68,803
Sales/Revenue/Turnover
6.46
7.18
8.69
8.02
5.83
5.12
5.76
5.9
4.25
4.92
7.08
16.74
8.3
7.65
3.7
3.64
3.2
Operating Margin (%)
99
117
134
165
251
253
298
393
510
552
865
1,186
1,345
1,464
1,871
2,071
- -
Depreciation Expense
286
578
954
777
755
498
712
737
548
624
1,245
4,588
1,661
1,992
317
825
1,030
Net Income, GAAP
13.08
9.94
11.92
15.47
14.45
16.96
10.64
14.01
13.12
8.91
9.75
11.42
12.9
1.36
58.1
48.51
46.2
Effective Tax Rate (%)
4.02
5.65
8.26
6.35
5.23
3.1
4.54
4.1
2.37
2.46
4.25
13.08
4.13
4.93
0.66
1.36
1.5
Profit Margin (%)
3,318
3,626
3,852
5,345
4,734
4,120
4,290
4,608
4,187
2,304
404
5,049
2,263
-541
-53
2,542
4,585
Working Capital
1,678
1,770
1,555
387
469
200
1,449
2,755
2,396
2,115
5,026
6,273
12,591
13,009
17,038
18,561
20,574
LT Debt
3,331
3,761
4,763
8,061
8,040
8,172
8,406
9,725
10,047
10,353
10,706
15,016
16,719
18,287
17,915
20,616
20,596
Total Equity
7.66
10.81
12.61
9.36
6.85
6.28
7.22
7.03
5.63
6.65
8.86
21.16
9.81
8.44
1.81
2.48
2.43
Return on Invested Capital (%)
8.86
13.7
18.85
14.2
12.45
8.56
11.37
9.94
7.54
7.49
10.02
24.06
8.57
8.89
2.76
4.82
5.3
Return on Capital (%)
12.61
22.82
30.83
19.67
16.64
10.6
14.41
13.66
9.43
10.25
18.73
50.29
14.87
16.96
2.6
6.7
8.23
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
8,670
9,266
8,795
LT Borrowings
18,542
20,339
20,550
LT Finance Leases
20
20
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,637
2,637
2,637
Market Capitalization
23,057
29,148
27,196

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
23,907
26,156
25,234
Cash, Cash Equivalents & STI
3,575
5,571
4,501
Accounts Receivable, Net
8,548
7,674
8,617
Inventories
7,411
7,709
7,139
Total Current Liabilities
21,365
21,279
20,649
Payables & Accruals
- -
- -
- -
ST Debt
8,670
9,266
8,795
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.23%
14.8%
15.07%
Free Cash Flow
244.21%
-53.25%
-124.08%
Net Income, GAAP
43.5%
60.2%
160.36%
Sales/Revenue/Turnover
14.56%
15.95%
26.23%
Total Cash Common Dividend
20.13%
24.91%
-36.7%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
9,683
10,666
13,942
13,650
47,941
2024
10,510
12,837
17,118
20,050
60,514
2025
15,666
15,970
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.11
- -
- -
- -
0.12
2024
0.04
- -
- -
- -
0.31
2025
0.09
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.08
- -
- -
- -
0.68
2024
0.09
- -
- -
- -
0.43
2025
0.09
- -
- -
- -
- -
Similar Companies
Fujikura Kasei Co., Ltd. (4620.T)
Jiangsu Baichuan High-Tech New Materials Co., Ltd (002455.SZ)
Esken Limited (ESKNF)
JSR Corporation (4185.T)
Kingfa Science & Technology (India) Limited (KINGFA.BO)
Yip's Chemical Holdings Limited (YIPCF)
Business
Kingfa Sci. & Tech. Co., Ltd. Kingfa Sci. & Tech. Co., Ltd. engages primarily in the research, development, production, and sales of advanced chemical new materials, specializing in high-performance polymers and eco-friendly solutions. The company offers a comprehensive portfolio of core products, including modified plastics; eco-friendly high-performance recycled plastics; fully biodegradable plastics; specialty engineering plastics; carbon fiber and composite materials; light hydrocarbon and hydrogen energy materials; high-performance resins; and medical and healthcare polymer materials, which serve diverse applications in automotive, household appliances, modern agriculture, rail transportation, aerospace, high-end equipment, new energy, communications, electrical and electronic, and building decoration industries. Kingfa Sci. & Tech. Co., Ltd. operates globally, exporting to over 130 countries and regions and serving more than 1,000 renowned enterprises, with production and R&D bases in China, South Asia, North America, and Europe. Founded in 1993 and headquartered at No. 33 Kefeng Road, Guangzhou Science City, Hi-Tech Industrial Development Zone, Guangzhou, Guangdong Province, China, the company maintains 64 subsidiaries and emphasizes sustainable development through innovation in green materials. In recent developments, Kingfa Sci. & Tech. Co., Ltd. completes a significant equity buyback program announced on July 29, 2024, repurchasing 61,979,417 shares representing 2.33% of its capital; advances green low-carbon initiatives as evidenced by executive participation in COP30 discussions on advanced material solutions in 2025; and reports robust 2024 environmental progress, including 752 tonnes of recycled material utilization, alongside ongoing global R&D expansion and strategic collaborations in biomedical and hydrogen energy segments.